TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing
- PMID: 27495267
- PMCID: PMC8029292
- DOI: 10.1111/bpa.12424
TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing
Abstract
Intracellular inclusions consisting of TAR DNA binding protein-43 (TDP-43 pathology) are present in up to 57% of Alzheimer's disease (AD) cases and follow a distinct topographical pattern of progression described in the TDP-43 in AD staging scheme. This scheme has not been applied to the assessment of TDP-43 pathology in dementia with Lewy bodies (DLB) and aged controls. We investigated TDP-43 pathology prevalence and severity in AD, DLB, mixed AD/DLB (Mx AD/DLB) and aged controls. One hundred and nineteen human post-mortem brains were included, neuropathologically diagnosed as AD: 46, DLB: 15, Mx AD/DLB: 19 and aged controls: 39. Paraffin sections inclusive of the amygdala, hippocampus, striatum and neocortex were immunohistochemically stained with antibodies against phosphorylated TDP-43 and staged according to the TDP-43 in AD staging scheme. TDP-43 pathology was present in all groups: AD: 73.9%, DLB: 33.3%, Mx AD/DLB: 52.6% and controls: 17.9%. Prevalence of TDP-43 pathology was significantly higher in AD and Mx AD/DLB compared to controls. In controls, higher age at death was associated with prevalence of TDP-43 pathology and higher TDP-43 in AD stage, suggesting that this type of TDP-43 pathology may partly be an age-associated phenomenon. Significantly higher prevalence of TDP-43 pathology in the AD group indicates that AD pathology possibly triggers and aggravates TDP-43 pathology. The validity of the TDP-43 in AD staging scheme is not limited to AD and should be applied to assess TDP-43 pathology in post mortem brains of aged individuals to further elucidate the role of TDP-43 pathology in age associated neurodegeneration.
Keywords: Alzheimer's disease; Lewy body diseases; TDP-43; ageing; dementia with Lewy bodies; hippocampal sclerosis; mixed Alzheimer's disease and dementia with Lewy bodies.
© 2016 International Society of Neuropathology.
Conflict of interest statement
The authors declare they have no conflict of interest.
Figures


Similar articles
-
Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.Brain Res. 2007 Dec 12;1184:284-94. doi: 10.1016/j.brainres.2007.09.048. Epub 2007 Oct 25. Brain Res. 2007. PMID: 17963732
-
Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.Acta Neuropathol. 2015 May;129(5):729-48. doi: 10.1007/s00401-015-1406-3. Epub 2015 Mar 11. Acta Neuropathol. 2015. PMID: 25758940
-
Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies.Acta Neuropathol. 2009 Feb;117(2):125-36. doi: 10.1007/s00401-008-0480-1. Epub 2009 Jan 13. Acta Neuropathol. 2009. PMID: 19139911
-
The Differential Effects of Alzheimer's Disease and Lewy Body Pathology on Cognitive Performance: a Meta-analysis.Neuropsychol Rev. 2017 Mar;27(1):1-17. doi: 10.1007/s11065-016-9334-0. Epub 2016 Nov 22. Neuropsychol Rev. 2017. PMID: 27878426 Review.
-
Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.J Neural Transm (Vienna). 2018 Apr;125(4):615-650. doi: 10.1007/s00702-017-1821-9. Epub 2017 Dec 8. J Neural Transm (Vienna). 2018. PMID: 29222591 Review.
Cited by
-
Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation.Nat Rev Neurosci. 2021 Apr;22(4):197-208. doi: 10.1038/s41583-021-00431-1. Epub 2021 Mar 2. Nat Rev Neurosci. 2021. PMID: 33654312 Review.
-
Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model.Alzheimers Dement. 2019 Sep;15(9):1133-1148. doi: 10.1016/j.jalz.2019.02.002. Epub 2019 Aug 1. Alzheimers Dement. 2019. PMID: 31378574 Free PMC article.
-
Neuropathological associations of limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) differ between the oldest-old and younger-old.Acta Neuropathol. 2022 Jul;144(1):45-57. doi: 10.1007/s00401-022-02432-5. Epub 2022 May 12. Acta Neuropathol. 2022. PMID: 35551470 Free PMC article.
-
The cellular expression and proteolytic processing of the amyloid precursor protein is independent of TDP-43.Biosci Rep. 2020 Apr 30;40(4):BSR20200435. doi: 10.1042/BSR20200435. Biosci Rep. 2020. PMID: 32301481 Free PMC article.
-
Cryptic amyloidogenic regions in intrinsically disordered proteins: Function and disease association.Comput Struct Biotechnol J. 2021 Jul 26;19:4192-4206. doi: 10.1016/j.csbj.2021.07.019. eCollection 2021. Comput Struct Biotechnol J. 2021. PMID: 34527192 Free PMC article.
References
-
- Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K et al (2009) Phosphorylated TDP‐43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol 117:125–136. - PubMed
-
- Braak H, Braak E (1991) Neuropathological stageing of Alzheimer‐related changes. Acta Neuropathol 82:239–259. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical